NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
Latest Information Update: 27 Jul 2022
At a glance
- Drugs NP 137 (Primary)
- Indications Carcinoma; Endometrial cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms NP137
- 22 Jul 2022 Status changed from active, no longer recruiting to completed.
- 17 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Jun 2022.
- 17 May 2022 Status changed from recruiting to active, no longer recruiting.